Activated protein C: do more survive?
- 15 October 2005
- journal article
- editorial
- Published by Springer Nature in Intensive Care Medicine
- Vol. 31 (12) , 1624-1626
- https://doi.org/10.1007/s00134-005-2829-4
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Forums for Expressing ConcernsCritical Care Medicine, 2005
- Substantiating the concerns about recombinant human activated protein C use in sepsis*Critical Care Medicine, 2004
- Why are physicians so skeptical about positive randomized controlled clinical trials in critical care medicine?Intensive Care Medicine, 2004
- The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *Critical Care Medicine, 2004
- Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial *Critical Care Medicine, 2004
- Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)Chest, 2004
- Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shockCritical Care Medicine, 2004
- Assessing the Use of Activated Protein C in the Treatment of Severe SepsisNew England Journal of Medicine, 2002
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001